Tower Research Capital (TRC)’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-286
| Closed | -$3K | – | 4451 |
|
|
2017
Q3 | $3K | Buy |
+286
| New | +$3.15K | ﹤0.01% | 3531 |
|
|
2017
Q1 | – | Sell |
-974
| Closed | -$11K | – | 4491 |
|
|
2016
Q4 | $11K | Buy |
+974
| New | +$9.74K | ﹤0.01% | 2618 |
|
|
2016
Q3 | – | Sell |
-3,259
| Closed | -$43K | – | 5077 |
|
|
2016
Q2 | $43K | Buy |
3,259
+3,221
| +8,476% | +$42.2K | ﹤0.01% | 1673 |
|
|
2016
Q1 | $0 | Sell |
38
-5,912
| -99% | -$52.6K | ﹤0.01% | 5487 |
|
|
2015
Q4 | $55K | Buy |
+5,950
| New | +$49.8K | 0.01% | 514 |
|
|
2015
Q3 | – | Sell |
-17,982
| Closed | -$176K | – | 5281 |
|
|
2015
Q2 | $176K | Buy |
17,982
+17,882
| +17,882% | +$163K | 0.02% | 439 |
|
|
2015
Q1 | $1K | Sell |
100
-6,292
| -98% | -$50.1K | ﹤0.01% | 4253 |
|
|
2014
Q4 | $56K | Buy |
+6,392
| New | +$51.7K | 0.01% | 968 |
|
|
2014
Q2 | – | Sell |
-2,320
| Closed | -$11K | – | 5024 |
|
|
2014
Q1 | $11K | Buy |
2,320
+1,320
| +132% | +$6.38K | ﹤0.01% | 2546 |
|
|
2013
Q4 | $5K | Sell |
1,000
-4,333
| -81% | -$20.9K | ﹤0.01% | 3582 |
|
|
2013
Q3 | $27K | Buy |
5,333
+5,133
| +2,567% | +$28.6K | ﹤0.01% | 2466 |
|
|
2013
Q2 | $1K | Buy |
+200
| New | +$952 | ﹤0.01% | 3806 |
|
Tower Research Capital (TRC)'s SCLN Position: Q4 2017 in Review
Tower Research Capital (TRC) sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 286 shares — an estimated $3K sold.
Tower Research Capital (TRC) first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $176K in Q2 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Tower Research Capital (TRC) reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Tower Research Capital (TRC) sold 286 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $3K.
- Tower Research Capital (TRC) first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
- Tower Research Capital (TRC)'s Sciclone Pharmaceuticals Inc position peaked at $176K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.